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Abstract Drug-resistant tuberculosis is a growing threat
to global public health. Recent efforts to understand the
evolution of drug resistance have shown that changes in
drug–target interactions are only the first step in a longer
adaptive process. The emergence of transmissible drug-
resistant Mycobacterium tuberculosis is the result of a
multitude of additional genetic mutations, many of which
interact, a phenomenon known as epistasis. The varied
effects of these epistatic interactions include compensating
for the reduction of the biological cost associated with the
development of drug resistance, increasing the level of
resistance, and possibly accommodating broader changes
in the physiology of resistant bacteria. Knowledge of these
processes and our ability to detect them as they happen
informs the development of diagnostic tools and better
control strategies. In particular, the use of whole genome
sequencing combined with surveillance efforts in the field
could provide a powerful instrument to prevent future
epidemics of drug-resistant tuberculosis.
1 Introduction
The burden of tuberculosis (TB) caused by drug-resistant
Mycobacterium tuberculosis is increasing. As a result, the
standard treatment—directly observed therapy, short
course (DOTS), composed of 2 months of a four-drug
regimen (isoniazid [INH], rifampicin [RIF], pyrazinamide
[PZA], and ethambutol [EMB]) followed by 4 months of
treatment with RIF and INH—is failing in many settings.
While any degree of drug resistance might worsen the
prognosis of a TB patient [1, 2], there are two definitions of
M. tuberculosis drug resistance that are particularly rele-
vant in the clinic. The first refers to strains resistant to both
INH and RIF and is termed multidrug-resistant (MDR) TB.
Treatment of patients with MDR-TB takes up to 2 years,
and currently relies on fluoroquinolones (FQ) and inject-
able aminoglycosides (AG) to compensate for the loss of
two of the most potent drugs. The acquisition of resistance
to these classes of antibiotics defines extensively drug-
resistant (XDR) TB. XDR-TB requires even longer treat-
ment with drugs that are much more costly and show
limited efficacy and increased side effects. Thus, XDR-TB
is often associated with poor treatment outcomes [3].
The global genetic diversity of drug-resistant M. tuber-
culosis [4–10] indicates that drug resistance evolved on
multiple occasions in geographical hotspots characterized
by a high incidence of TB and inappropriate drug treat-
ment. The latter is mostly driven by a lack of resources
resulting in two important failures: an inability to detect
drug resistance and a systemic failure to deploy effective
treatments [11–13]. The ongoing evolution of M. tuber-
culosis in these settings [14, 15], provides an excellent
opportunity to explore the genetic determinants of drug
resistance in this microbe.
Unlike most other bacterial pathogens, resistance plas-
mids and horizontal gene transfer play no role in the
acquisition of drug resistance in M. tuberculosis. More-
over, efflux mechanisms appear to serve only as a ‘stepping
stone’ to high-level resistance. They allow the bacteria to
tolerate higher levels of drug but do not per se result in
clinically relevant levels of resistance to multiple antibi-
otics in M. tuberculosis [14, 16–18]. Instead, the evolution
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of strains resistant to multiple antibiotics is driven by the
sequential acquisition and accumulation of resistance-
conferring mutations on the bacterial chromosome. These
mutations primarily interfere with drug-target binding (e.g.
RIF-rpoB [19], FQ-gyrA [20]), compromise prodrug acti-
vation (e.g. INH-katG [21], PA-824-fgd [22]), or cause
over-expression of the target (INH/ETH—promoter region
of inhA). The elucidation of the mechanisms of action for
many antimycobacterials led to the identification of key
determinants of resistance (see Zhang and Yew [23] and
Almeida Da Silva and Palomino [24] for reviews), and the
realization that the corresponding genetic mutations can be
used as reliable molecular markers for drug susceptibility
testing (DST) [25]. The application of this knowledge to
the clinic has resulted in the development of diagnostic
tools based on nucleic acid amplification (NAA) that
overcome many of the shortcomings of phenotypic DST;
these include a long turnaround time, outcome variability,
and infrastructure requirements [26–29]. A comprehensive
overview of these diagnostic tools has been given else-
where [30]. Recently, one of these tools, known as Xpert
MTB/RIF, has been the subject of a policy update pub-
lished by the World Health Organization. Their recom-
mendation for Xpert MTB/RIF to replace microscopy in
HIV-positive patients, patients suspected of MDR-TB, and
those suspected of TB meningitis follows its successful
implementation in many countries [31, 32]. The instrument
is designed to analyse sputum directly, hence bypassing the
need for primary bacterial culture. It simultaneously tests
for the presence of M. tuberculosis and RIF resistance.
Even though this technology is having a positive impact on
TB control by offering high sensitivity and reducing the
time to TB diagnosis, the associated costs and infrastruc-
tural requirements (e.g. a constant power supply, machine
maintenance) remain limiting for many high-burden
countries [32, 33]. Hence, on-going efforts in product
development focus on cheaper and simpler so-called
‘point-of-care’ diagnostics [34]. Nonetheless, DST without
bacterial culturing will continue to require NAA. The
choice of targets for NAA will determine the power of
future diagnostics. It should be based on detailed knowl-
edge of the relationship between strain genotype, drug
resistance phenotype, and the patient treatment outcome in
terms of relapse rate and treatment failure. Whole genome
sequencing (WGS) of clinical drug-resistant strains of M.
tuberculosis should be combined with the analysis of
clinical information from patients infected by these strains
to yield valuable new insights into the biology of drug
resistance.
In this review, we first summarize key findings from
recent WGS studies of mycobacterial drug resistance. We
focus specifically on results that shed light on why the
acquisition of individual drug resistance-conferring
mutations is only part of the problem. We then use specific
examples to illustrate how understanding more broadly the
evolutionary mechanisms that drive drug resistance can
inform the development of improved diagnostic tools as
well as better strategies to preserve both existing and new
treatment regimens.
2 New Genomic Insights into Mycobacterium
tuberculosis Drug Resistance
The evolutionary path leading through drug resistance is
strongly influenced by two factors: epistasis and bacterial
fitness [35–38]. We define epistasis as a set of genetic
interactions where the phenotypic effect of one mutation is
determined by the presence of one or more other mutations.
For example, resistant strains carrying the same resistance
mutations vary in their capacity to transmit from patient to
patient [39–42], showing that the strain genetic background
can determine the course of evolution of drug resistance.
Bacterial fitness, on the other hand, is a function of growth
rate, virulence, and transmissibility [15, 43]. Any mutation
that reduces it in relation to the wild-type strain is said to
carry a ‘fitness cost’. The most immediate way to estimate
the relative fitness is to measure the growth rate of bacteria
in culture. On average, most drug-resistance mutations
carry a fitness cost (see Fig. 3) [44] whose magnitude
positively correlates with the frequency of different resis-
tance mutations in the clinic; resistant strains with the
smallest fitness defect are most abundant [45, 46]. Further-
more, the fitness of resistant mutants is not fixed; evolution
is an ongoing process, and a comparison between clinical
and laboratory strains carrying the same drug-resistance
mutation shows that clinical strains often successfully
bypass any fitness cost imposed by resistance [45]. The
acquisition of such compensatory mutations is also an
example of epistasis and is key in the evolution of trans-
missible drug-resistant strains that pose the greatest risk to
public health [6, 10, 47–51]. Unfortunately, we do not cur-
rently have sufficient knowledge to predict epistatic inter-
actions a priori, so we must rely on detecting them
empirically by studying the genetics of drug resistance [52].
A number of recent studies used WGS to address the
evolution of drug-resistant M. tuberculosis [7, 9, 51, 53,
54]. The authors of these studies used approaches based on
phylogeny [7], molecular epidemiology [9, 51, 53], and
mutation frequency analyses [54] to compare drug-sus-
ceptible and drug-resistant clinical strains of M. tubercu-
losis. The shared aim of these studies was the identification
of bacterial genes under positive evolutionary selection by
drug pressure. The detailed discussion of the merits and
shortcomings of the analytical approaches used in these
studies is beyond the scope of this review, but it is
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important to note that there is considerable overlap in the
findings of these studies. In addition to known drug targets,
all studies identified novel bacterial genes and intergenic
regions whose function may be ancillary to drug-resistance
mutations (see Fig. 1). In particular, several genes involved
in lipid metabolism, cell wall homeostasis, purine metab-
olism, and transcriptional control appear to be positively
selected in presence of anti-TB drugs [7, 54]. These studies
represent an important step towards an improved under-
standing of drug resistance. However, with the exception of
just a few mutations (e.g. ponA1, and the promoters of thyA
and thyX [7, 54]), the actual role of these genes remains
unclear, essentially offering an extended list of genes of
interest that require further investigation. Consequently, it
is currently not possible to evaluate the role of these genes
in the development of future diagnostics or therapies.
In addition to the above genes, there are a growing
number of novel genes for which experimental evidence is
available to support a role of epistasis in adaptation to
resistance. These genes were identified through recent
studies aimed at elucidating the evolutionary trajectory of
drug-resistant M. tuberculosis in the clinic [6, 47] and
include rpoC, which mediates the adaptation to RIF
resistance, and Rv3806c, which appears to have a role in
EMB resistance. RIF resistance is caused by mutations of
the beta subunit of RNA polymerase encoded by rpoB.
Mutated amino acids are normally involved in drug binding
and are usually restricted within a short stretch of the
protein termed the rifampicin resistance determining region
(RRDR) [19]. Many of these mutations carry a fitness cost
[45, 49] that appears to be negatively correlated with the
activity of the mutant enzyme [55]. The importance of this
Fig. 1 A web of epistasis mediates drug resistance in M. tubercu-
losis. Key genes in M. tuberculosis drug resistance have been plotted,
taking into account their approximate position in the genome. Genes
in bold are known to be directly involved in antibiotic resistance.
Lines denote putative epistatic interactions; connecting genes
involved in the physiology of a drug as well as more broad/indirect
mechanisms referred to as ‘ancillary to drug resistance’. This
categorization is meant to include factors mediating complex aspects
of cell physiology, such as cell permeability and mutation-induced
physiological changes. Bold lines connecting rpoB to rpoC and embB
to Rv3972 refer to in vitro validated compensatory mechanisms.
Specific mutation pairs using M. tuberculosis numbering are shown
where known. Figure based on information from the following
references: [6, 7, 24, 46, 47, 49, 51, 54, 91–94]. AG aminoglycosides,
EMB ethambutol, ETH ethionamide, FQ fluoroquinolones, INH
isoniazid, PAS para-aminosalicylic acid, PZA pyrazinamide, RIF
rifampicin, STR streptomycin. Many ancillary genes were omitted for
the sake of clarity—see original papers for a more comprehensive list
[7, 54]
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aspect of RNA polymerase physiology is clearly illustrated
by the fact that one of the most frequent resistance muta-
tions observed in the clinic, S450L, (equivalent to S531L in
Escherichia coli) also carries the lowest fitness cost [45].
Moreover, this mutation appears to be almost ubiquitous
among MDR strains of M. tuberculosis [6, 9, 10, 48, 51],
and perhaps more importantly, is shown to be strongly
associated with the acquisition of compensatory mutations
within RNA polymerase genes (rpoA, rpoB, and rpoC).
This combination of mutations is strongly associated with
improved transmissibility of strains as evidenced by clonal
expansion of M. tuberculosis strains carrying these partic-
ular mutations in patient populations [9, 48, 51]. The role
of these compensatory mutations (see Koch et al. [56] for a
more comprehensive review) appears to be to restore wild-
type function of mutant RNA polymerase, probably on the
level of enzymatic activity [49, 50]. Alternatively, these
compensatory mutations maybe also restore the baseline
gene expression profile of cells. Specifically, rpoB mutants
were shown to have a modified lipid profile [57] as well as
a modified expression of many proteins involved in lipid
metabolism, particularly phthiocerol dimycocerosates
(PDIMs) [58]. Interestingly, lipid metabolism genes,
including those for PDIM metabolism, seem to be under
positive selection during the evolution of drug resistance
[7, 54]. Because PDIMs and other mycobacterial lipids
play an important role in virulence [59, 60], this argues that
global physiological consequences of drug-resistance
mutations could provide a contextual framework, within
which the compensatory mechanisms mediated by muta-
tions in ancillary genes can be explored [7, 51, 54].
A recent set of experiments reported by Safi et al. [47]
demonstrate the effect of epistasis in the progressive increase
of minimal inhibitory concentration (MIC) for a drug.
Focusing their study on EMB, they observed that acquisition
of high-level resistance to EMB is a multistep process. In
addition to the most frequently isolated resistance mutant—
embB M306V—they identified nonsynonymous mutations
in Rv3806c and a synonymous mutation in Rv3792 as
important contributors to EMB resistance in vitro. They
proceeded to show that Rv3806c is involved in modulating
the availability of EmbB substrates, while the synonymous
single nucleotide polymorphism in Rv3792 apparently sta-
bilized embC RNA, leading to a de facto over-expression of
the gene, resulting in reduced susceptibility to EMB [47].
Finally, epistasis is not limited to the physiology of a
single drug. Investigations into the interaction between
mutations resulting in resistance to disparate drugs have
suggested that positive epistasis may drive multidrug
resistance [61]. Our group recently published a report
showing that specific resistance mutations in rpoB and
gyrA can compensate for each other’s fitness defects, to the
point that some strains carrying both mutations are fitter
than either single mutant [46]. Moreover, the particular
combinations of mutations conferring resistance to RIF and
ofloxacin (OFX) associated with the highest overall fitness
appear to be positively selected in high-burden settings.
The examples listed here are not designed to offer a
comprehensive overview of all reported examples of
epistasis in drug-resistant M. tuberculosis; we have tried to
sketch a more complete picture in Fig. 1. Instead, they
were chosen to illustrate important concepts brought to
light by recent studies: in the first place, based on current
data, it appears that compensatory mutations occur most
frequently in strains that already harbor the least costly
mutation [48]. Second, epistatic interactions occur between
specific mutations [46, 47, 49], and in some cases these can
be mutually exclusive; for example, a strain harboring an
rpoA mutation does not then also acquire an rpoC or
additional rpoB mutations [6, 50, 51, 62]. Continued
exposure to a drug seems to impose constraints on evolu-
tion that facilitate the acquisition of compensatory muta-
tions in strains that are already resistant [36, 50]. Once
generated, these strains are more likely to be transmitted
than strains carrying the resistance mutation alone [48, 51].
A further consequence of continued drug exposure is the
stepwise accumulation of mutations that result in an
increased level of resistance to a drug [47]; a factor that is
already influencing INH resistance in XDR strains [63] and
may contribute to higher levels of resistance to FQ [64, 65].
Moreover, epistasis can occur between drug-resistance
mutations [46, 61, 66], implicating individual resistance
determinants as drivers of polydrug resistance. Combined,
these observations clearly indicate that continued inap-
propriate treatment, in part caused by misdiagnosis of
resistance, drives the evolution of more transmissible,
increasingly drug-resistant strains [10, 51].
A further set of factors, not considered hitherto, is
involved in the generation of protein heterogeneity in the
cell. The primary source of this is mutations, and mutation
rates were shown to vary between different phylogenetic
lineages of M. tuberculosis. The Beijing family of strains in
particular seems to have a higher mutation rate [67–69].
The exact consequences of this remain to be determined,
but differences in mutation rate have been used to explain
the correlation between this genotype with a higher rate of
drug-resistance acquisition. Mathematical models estimate
that Beijing strains are 22-fold more likely to produce
MDR strains [68]. Another intriguing possibility was
recently put forward by Javid et al. [70], who argue that
protein variability driven by errors in the central informa-
tion-processing pathway (DNA-RNA-protein) may provide
a phenotypic stepping-stone to resistance akin perhaps to
other ancillary mechanisms shown in Fig. 1. While
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intellectually appealing, the clinical relevance of such a
scenario remains to be substantiated.
3 Implications for Diagnosis and Therapy
The translational potential of the knowledge gained from
the above studies lies in the implementation of molecular
tools in TB control (see Table 1 for a summary). Wells
et al. [71] offer an excellent review of current and future
needs for the clinical management of TB, addressing
diagnostics, surveillance, and programmatic approaches. It
is useful to take advantage of their conceptual framework
to discuss the impact of the themes that emerge from
evolutionary studies. They place capabilities available to
TB control programs onto a continuum that spans from
community-based physicians to supranational reference
laboratories (see Fig. 2). Accordingly, the available
resources combined with the specific needs of each level
will dictate the contribution that molecular approaches can
offer.
In the clinic, the main goal is rapid and effective treat-
ment of infected individuals. This relies on quick and
reliable case detection, and, given the need for speed, is
likely to depend on molecular diagnostics in the future
[71]. In this setting, focusing on drug-resistance mutations
offers high sensitivity and specificity for key first-line
drugs [25]. Including compensatory mutations (e.g. in rpoC
or rpoA, discussed above) as diagnostic markers is unlikely
to provide additional clinical benefit, because mutations in
rpoB already display a high sensitivity and specificity for
detecting MDR-TB in individual patients [33, 72]. In
contrast, a key area in which evolutionary lessons could be
brought to bear in a significant manner is surveillance.
Consider the reproductive number of a pathogen (R0, see
Fig. 3). Two dimensions are paramount to the outcome of
transmission cycles; one is pathogen transmissibility
(t) and the other is time to effective treatment (c 9 d).
Strain fitness plays a role in the former, while drug resis-
tance considerably influences the latter. It is in the interest
of public health to identify and eradicate transmissible
drug-resistant strains quickly. We are currently failing on
this front—in 2012, fewer than one-quarter of estimated
MDR-TB cases were detected, and only 23 % of those had
DST results reported for PZA and FQ [73]. To this end,
there is scope for the implementation of ‘molecular diag-
nostics for public health’. Screening for the emergence of
compensatory mutations in a population, perhaps by
Table 1 Implications of understanding evolutionary mechanisms of drug resistance for tuberculosis control
Experimental observation Physiological consequence Implications
Resistant strains gain compensatory
mutations that change the basic
physiology, e.g. RIF-rpoC
Increased transmissibility, increased propensity to
acquire additional resistance
Focus surveillance on mutations that correlate
with transmissible, highly resistant strains
Use spent biosamples to establish wide
catchment area for WGS-based surveillance
Continued exposure to RIF directs
evolution towards the acquisition
of compensatory mutations
More rapid evolution of compensatory mutations Use molecular tools to probe the genotype of
strains and stop administering ineffective drugs
immediately
Epistasis exists between drug-
resistance mutations for a single
drug: e.g. EMB, FQ, INH, RIF
Multi-step acquisition of high level of drug resistance Define clinical breakpoint concentrations based
on specific susceptibility profiles for a drug
Positive epistasis between rpoB and
gyrA mutations
Strains with specific combinations of resistance
mutations (e.g. gyrA D94G and rpoB H445Y) are
fitter than the wild type
Drug regimens containing both RIF and FQ may
fail more quickly. Assess current clinical trials
for evidence
Evaluate if the order in which drugs are
administered might enhance negative epistatic
interactions
Some mutations conferring
resistance to FQ and bedaquiline
have no fitness costs attached
No need to compensate for specific resistance
mutations
Enforce appropriate administration of drugs to
avoid adding these antibiotics to failing
regimens or use as monotherapy
Explore the spectrum of resistance mutations,
identify low cost and frequent mutations before
releasing the drug into the market
Mutation rates vary between M.
tuberculosis lineages
Beijing family strains acquire resistance to INH and
RIF at a higher rate and are 22 times more likely to
develop into MDR than the laboratory-adapted
strain
Increase frequency of phylogeny-based
surveillance and focus monitoring on areas
with high rates of Beijing strains
EMB ethambutol, FQ fluoroquinolones, INH isoniazid, RIF rifampicin, WGS whole genome sequencing
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focusing on re-treatment cases [74] to pinpoint areas with
evolved highly transmissible strains as they emerge [48,
51], would aid the public health official to prioritize
resource allocation and interrupt the spread of these strains.
Examples of such measures include targeted delivery of
individualized, albeit expensive treatments, resource-
intensive active case finding, and, in extreme cases, isola-
tion [75, 76]. In line with the described differences in
mutation rates between M. tuberculosis lineages [67, 68],
the public health official may include phylogenetic markers
to focus monitoring on areas with a high incidence of
Beijing strains. Performing surveillance based on high-
resistance mutations alone may be insufficient. Mutations
conferring intermediate resistance, namely, below that of
empirically determined resistance breakpoints, play a
potentially pivotal role in the spread of resistance [47]. We
have used the ‘fitness-MIC space’ to illustrate these con-
cepts in Fig. 3. It is also important to stress at this point,
that strains harboring mutations conferring low-level
resistance can often be treated effectively with existing
drugs [77], either by increasing the dosage of the same
drug, or by using alternative drugs from the same class, as
is the case of FQ [78]. Conversely, the use of ineffective
drugs should be stopped immediately to avoid directing the
evolution of a strain [36, 50] towards a more transmissible
phenotype.
In addition to surveillance, knowledge of epistasis
should be applied to the design and deployment of future
drug regimens. Given the genetic interaction between
mutations in rpoB and gyrA [46], it may be dangerous to
administer RIF and FQ simultaneously, and should perhaps
be avoided. A number of current clinical trials are testing
an iteration of such a combination [79], and their outcomes
should be carefully scrutinized by using WGS for evidence
of epistasis-driven drug resistance [74, 80–82]. Protecting
new drug classes is equally important. Bedaquiline is the
first new antimycobacterial to be approved by the US FDA
for over 40 years [83, 84]. Given the availability of be-
daquiline resistance mutations with no fitness cost, or even
a fitness benefit (see Fig. 3) [85], it is key that the guide-
lines for the administration of the drug are adhered to [86,
87], especially in light of the fact that no standardized
regimen exists for it yet. Most importantly, bedaquiline
should not be used to rescue a failing regimen, and should
Fig. 2 The healthcare continuum. A diagrammatic representation of
the current healthcare continuum as described in Wells et al. [71],
showing different healthcare levels with their distance from the
patient. The resources dimension encompasses a breadth of param-
eters, from access to infrastructure and apparatus, to technical
proficiency of staff and financial resources that are available.
Different diagnostic and DST technologies are shown as bars with
the arrows indicating the levels at which we would ideally deploy
them in the future. WGS whole genome sequencing, LPA line probe
assay, MGIT mycobacterial growth indicator tube: phenotypic DST
using the Bactec MGIT 960 instrument, automated NAT automated
nucleic acid amplification technology
Fig. 3 Evolutionary trajectories of epistasis-driven resistance. The
relative fitness of strains carrying key drug-resistance mutations
grown in the absence of drug was plotted against their contribution to
MIC to illustrate the relationship between genotype and phenotype for
important drug-resistance mutations. Lines connecting individual
mutations denote strains carrying two mutations, while arrows denote
estimates of the fitness of double/triple-mutants (three different types
of arrows are used to illustrate different evolutionary trajectories).
Reproductive number (R0) defined as the number of secondary cases
caused by an infected individual is roughly equal to the product of an
organism’s transmissibility (t), number of contacts (c), and the
duration of infection (d). Fitness estimates were summarized from
Gagneux et al. [45] (RIF, M. tuberculosis), Borrell et al. [46] (FQ,
Msm), Safi et al. [47] (EMB, M. tuberculosis), and Huitric et al. [85]
(BDQ, M. tuberculosis). We were unable to find true relative fitness
measurements for KatG S315T and GyrA A90V; these were
estimated from Pym et al. [95] and Poissy et al. [96]. Fold increases
in MIC shown are averages of values obtained from Sougakoff et al.
[97–99], Pang et al. [97–99], and Anthony et al. [97–99] for RIF; Pym
et al. [95] for INH; Safi et al. [47, 100, 101], Plinke et al. [47, 100,
101], and Starks et al. [47, 100, 101] for EMB; Aubry et al. [94, 102–
105], Matrat et al. [94, 102–105], Cheng et al. [94, 102–105], Duong
et al. [94, 102–105], and Malik et al. [94, 102–105] for FQ; and
Huitric et al. [85] for BDQ. BDQ bedaquiline, EMB ethambutol, FQ
fluoroquinolones, INH isoniazid, MIC minimum inhibitory concen-
tration, RIF rifampicin
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always be administered with other effective drugs to min-
imize the emergence of resistance.
4 Conclusion
Consensus is growing that biological parameters such as
the frequency of resistance mutations, the occurrence of
low- or no-cost drug-resistance mutations, epistasis
between resistance mutations, as well as host genetics
should be considered when deciding on future treatment
protocols [88]. Efficient inclusion of all of these factors for
drug-resistance surveillance requires broader implementa-
tion of WGS. The World Health Organization is currently
analyzing the results of a surveillance effort looking for
underlying resistance to PZA and FQ where phenotypic
DST was paired with DNA sequencing (Zignol, unpub-
lished). The timing of the study is crucial in view of the
fact that many of the new treatment regimens under
investigation rely on these two drugs, and underlying
resistance may severely compromise their success.
Applying WGS to clinical trials can also contribute
important information on the success of a new treatment
[81], as well as sorely needed data for new-in-class anti-
biotics such as PA-824, delamanide, bedaquiline, and
SQ109 [89]. Together, this knowledge should be used to
build an accurate picture of how the genetic makeup of a
strain ultimately determines the success of treatment.
Due to high costs and logistical requirements, WGS
technology might not find its way into many of the most
affected and often resource-poor countries in the short term.
However, applied at a supranational or national level with a
wide-spread community-based catchment area, WGS would
allow high-throughput analysis of known but also unknown
mutations. Healthcare officials would thus obtain surveil-
lance data and essential information for the development of
new diagnostic tests adjusted to the prevailing resistance
pattern [39, 40, 42, 90]. For example, one could imagine an
approach in which used sputum-microscopy slides from
primary TB-diagnostic centers are recycled as a source of M.
tuberculosis DNA for pooled DNA sequencing to measure
the frequency of drug-resistance alleles in a particular patient
population. Similarly, spent DST samples, such as myco-
bacterial growth indicator tubes (MGIT) and Loewenstein–
Jensen slopes, would provide an excellent source of DNA for
WGS-based surveillance. The application of WGS and
evolutionary principles to drug resistance in M. tuberculosis
has been furthering our understanding of the challenges
faced in the clinic as well as contributing key data for
developing tools and strategies to control drug-resistant TB.
As new treatment regimens containing new drugs are
implemented, we will have to establish the spectrum of
epidemiologically relevant mutations as soon as possible.
This will help us track the emergence of strains resistant to
these drugs in real-time, thereby prolonging the life span of
the new regimens—a fundamental concern given how pre-
cious new drugs are.
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